Research progress on individualized administration of linezolid based on population pharmacokinetics
- VernacularTitle:基于群体药动学的利奈唑胺个体化给药研究进展
- Author:
Hongyu QIU
1
,
2
;
Li RONG
1
,
2
;
Mengyuan XIE
1
,
2
;
Lingti KONG
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of Bengbu Medical College，Anhui Bengbu 233004，China
2. School of Pharmacy，Bengbu Medical College，Anhui Bengbu 233030，China
- Publication Type:Journal Article
- Keywords:
linezolid;
population pharmacokinetics;
antibacterial;
individualized administration
- From:
China Pharmacy
2023;34(5):636-640
- CountryChina
- Language:Chinese
-
Abstract:
Linezolid is an antibacterial agent for the treatment of multi-resistant Gram-positive bacterial infections， which is widely used in clinical practice. However， there are large individual differences in the pharmacokinetic characteristics of the drug in patients， and it is difficult to obtain the optimal therapeutic effect when the drug is administered according to the conventional dose in the instructions. Therefore， it is necessary to carry out therapeutic drug monitoring （TDM） for linezolid， and guide and optimize its antibacterial treatment plan by using population pharmacokinetics （PPK） and pharmacodynamics principles. This paper summarizes the PPK changes and the research progress of individualized administration of linezolid in various populations， and recommends that the patient’s steady-state blood concentration is kept at 2-8 mg/mL through TDM when using linezolid clinically. It is recommended to appropriately reduce the dosage for patients with liver and kidney dysfunction， appropriately increase the dosage for obese， burned and children patients， and provide pharmaceutical monitoring during the medication process to promote rational drug use.
